Hosted on MSN5h
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...
GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
GSK rises Wednesday, outperforms market
GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.
Why GSK Stock Is Surging Today
GSK generated earnings per share of 23.2 pence last quarter, versus analysts’ average estimate of 20 pence. Last quarter, its ...
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...
FiercePharma4h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Zacks.com on MSN7h
GSK (GSK) Tops Q4 Earnings and Revenue Estimates
Glaxo (GSK) delivered earnings and revenue surprises of 11.32% and 4.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
bovnews1d
GSK’s Unexpected Plunge: What’s Next?
On Monday, GSK plc (GSK) stock saw a decline, ending the day at $34.9 which represents a decrease of $-0.37 or -1.05% from the prior close of $35.27. The stock opened at $34.87 and touched a low of ...
GSK falls Tuesday, underperforms market
GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.
FTSE 100 movers: GSK surges on guidance; DCC in the red
Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...